Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Equity Income (2024 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Equity Income for 2 consecutive years, with $249000.0 as the latest value for Q4 2025.

  • Quarterly Equity Income rose 112.46% to $249000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, down 55.56% year-over-year, with the annual reading at $2.8 million for FY2025, 55.56% down from the prior year.
  • Equity Income hit $249000.0 in Q4 2025 for Ani Pharmaceuticals, down from $3.1 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $9.7 million in Q1 2024 to a low of -$2.7 million in Q2 2024.